SCHEMBL3331196

SCHEMBL3331196

CCCCOC(=O)N1CCN(C(=O)CNC)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
POLB P06746 3/20 0.56
LMNA P02545 1/20 0.56
ALDH1A1 P00352 7/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 3/20 0.44
HRH2 P25021 2/20 0.43
HRH1 P35367 2/20 0.43
MAPT P10636 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
P2RY12 Q9H244 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3334291 0.85 ALDH1A1 (0.62) SMN1; SMN2POLBALDH1A1HTTKDM4E
SCHEMBL9405372 0.85 POLB (0.73) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL523279 0.81 SMN1; SMN2 (0.59) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL524083 0.79 ALDH1A1 (0.56) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL5594524 0.78 POLB (0.65) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL5594520 0.78 POLB (0.65) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL14590615 0.78 POLB (0.65) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL27826063 0.78 SMN1; SMN2 (0.65) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL1859157 0.78 SMN1; SMN2 (0.69) SMN1; SMN2POLBLMNAALDH1A1HTT
SCHEMBL6129170 0.78 POLB (0.64) SMN1; SMN2POLBLMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669266-B2 Quinoline-carboxamide derivatives as P2Y12 antagonists SANOFI (FR) 2014-03-11 US disclosed
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-06-03 US disclosed
EP-2148871-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-02-03 EP disclosed
WO-2008128647-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY1, P2RY2 SMN1; SMN2 4406/4885POLB 1874/4885LMNA 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.